AIDX — 20/20 Biolabs Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
20/20 Biolabs Inc, formerly 20/20 GeneSystems, Inc., is a digital diagnostics company, which is engaged in developing and commercializing clinical laboratory tests and associated software that is powered by machine learning and real-word data to improve diagnostic accuracy and clinical usefulness. The Company offers OneTest, a simple blood test for multiple cancers, harnesses the power of Artificial Intelligence (AI) to help identify the disease at an earlier, more treatable stage. Onetest helps detect Lung, Liver, Pancreatic, Prostate, Kidney, Ovarian and many other cancers with a single blood test.
Directors
- Last Annual
- Last Interim
- Incorporated
- August 7th, 2000
- Public Since
- January 1st, 1970
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Address
- 9430 Key West Avenue, Suite 100, ROCKVILLE, 20850
- Web
- https://2020gene.com/
- Phone
- +1 2404536339
- Auditors
Similar to AIDX
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Alpha Tau Medical
NASDAQ Capital Market
FAQ
As of Today at 19:00 UTC, shares in 20/20 Biolabs are trading at $1.83. This share price information is delayed by 15 minutes.
Shares in 20/20 Biolabs last closed at $1.83 and the price had moved by over the past 365 days. In terms of relative price strength the 20/20 Biolabs share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out more20/20 Biolabs does not currently pay a dividend.
20/20 Biolabs does not currently pay a dividend.
20/20 Biolabs does not currently pay a dividend.
To buy shares in 20/20 Biolabs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.83, shares in 20/20 Biolabs had a market capitalisation of .
Here are the trading details for 20/20 Biolabs:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AIDX
Based on an overall assessment of its quality, value and momentum 20/20 Biolabs is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 20/20 Biolabs. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $1.83, shares in 20/20 Biolabs were trading -55.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 20/20 Biolabs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on 20/20 Biolabs' directors